View More Recent Stories

Jan 31, 2024 07:01AM InspireMD (NSPR) Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Jan 31, 2024 07:00AM InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Jan 3, 2024 07:00AM InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
Dec 20, 2023 07:00AM InspireMD (NSPR) Issued US Patent Covering SwitchGuard Neuroprotection System
Dec 20, 2023 07:00AM InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
Nov 27, 2023 07:03AM InspireMD (NSPR) Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
Nov 27, 2023 07:00AM InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
Nov 6, 2023 07:00AM InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 1, 2023 02:20PM InspireMD (NSPR) Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. IDE Clinical Trial at VIVA23
Nov 1, 2023 02:19PM InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
Oct 12, 2023 07:00AM InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
Oct 3, 2023 07:03AM InspireMD (NSPR) Announces Senior Leadership Changes
Oct 3, 2023 07:00AM InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
Aug 31, 2023 08:00AM InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
Aug 8, 2023 07:00AM InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
Jun 26, 2023 08:00AM InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
May 18, 2023 08:00AM InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 16, 2023 07:00AM InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 08:01AM InspireMD (NSPR) Announces $113.6M Private Placement
May 15, 2023 08:00AM InspireMD Announces Private Placement of Up to $113.6 Million
May 1, 2023 08:00AM InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
Mar 30, 2023 07:00AM InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
View More Recent Stories